CLINICAL TRIALS PROFILE FOR TAVAPADON

Clinical Trials for Tavapadon

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT04201093 ↗	Fixed-Dose Trial in Early Parkinson's Disease (PD)	Recruiting	Cerevel Therapeutics, LLC	Phase 3	The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD.
NCT04223193 ↗	Flexible-Dose Trial in Early Parkinson's Disease (PD)	Recruiting	Cerevel Therapeutics, LLC	Phase 3	The purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.
NCT04241393 ↗	An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects	Completed	Cerevel Therapeutics, LLC	Phase 1	The purpose of this trial is to determine the absorption, metabolism, and excretion (AME) of [14C] tavapadon.
NCT04542499 ↗	Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations	Recruiting	Cerevel Therapeutics, LLC	Phase 3	The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of "on" time without troublesome dyskinesia in L-Dopa-treated participants with Parkinson's Disease (PD) who are experiencing motor fluctuations.
NCT04760769 ↗	Open-label Trial in Parkinson's Disease (PD)	Recruiting	Cerevel Therapeutics, LLC	Phase 3	The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Parkinson's Disease.
NCT05404529 ↗	To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function	Recruiting	Cerevel Therapeutics, LLC	Phase 1	The primary purpose of the study is to assess the effect of hepatic impairment on the PK of tavapadon following administration of a single oral dose in participants with mild and moderate hepatic impairment relative to age, body weight, and sex-matched participants with normal hepatic function.
NCT05404542 ↗	To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function	Recruiting	Cerevel Therapeutics, LLC	Phase 1	The primary purpose is to assess the effect of renal impairment on the PK of tavapadon following administration of a single oral dose in participants with severe renal impairment relative to age, body weight, and sex-matched participants with normal renal function.

Clinical Trial Conditions for Tavapadon

Condition Name

Condition Name
Intervention	Trials
Parkinson Disease	6
Renal Impairment	1
Healthy Subjects	1
Hepatic Impairment	1

Condition MeSH

Condition MeSH
Intervention	Trials
Parkinson Disease	6
Renal Insufficiency	1
Liver Diseases	1

Clinical Trial Locations for Tavapadon

Trials by Country

Trials by Country
Location	Trials
United States	76
Australia	12
Poland	10
Ukraine	8
Spain	7

Trials by US State

Trials by US State
Location	Trials
Florida	5
Texas	5
Ohio	4
Michigan	4
Illinois	4

Clinical Trial Progress for Tavapadon

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	4
Phase 1	5

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Recruiting	7
Not yet recruiting	1
Completed	1

Clinical Trial Sponsors for Tavapadon

Sponsor Name

Sponsor Name
Sponsor	Trials
Cerevel Therapeutics, LLC	9

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	9